Skip to main content
SpringerLink
Log in

Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients

  • Chapter
  • First Online:
Biological Mechanisms of Minimal Residual Disease and Systemic Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1100))

Abstract

Melanoma and breast cancer (BC) patients face a high risk of recurrence and disease progression after curative surgery and/or therapeutic treatment. Monitoring for minimal residual disease (MRD) during a disease-free follow-up period would greatly improve patient outcomes through earlier detection of relapse or treatment resistance. However, MRD monitoring in solid tumors such as melanoma and BC are not well established. Here, we discuss the clinical applications of MRD monitoring in melanoma and BC patients and highlight the current approaches for detecting MRD in these solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012–4021

    Article  PubMed  PubMed Central  Google Scholar 

  2. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui C-H, Campana D (2010) Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 115:4657–4663

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M (2013) A global review of melanoma follow-up guidelines. J Clin Aesthet dermatol 6:18

    PubMed  PubMed Central  Google Scholar 

  4. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ (2012) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:961–965

    Article  PubMed  Google Scholar 

  5. Kawahara A, Fukumitsu C, Azuma K, Taira T, Abe H, Takase Y, Murata K, Sadashima E, Hattori S, Naito Y (2018) A combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients. Cytopathology 29(2):150–155

    Article  CAS  PubMed  Google Scholar 

  6. Lin SY, Linehan JA, Wilson TG, Hoon DS (2017) Emerging utility of urinary cell-free nucleic acid biomarkers for prostate, bladder, and renal cancers. Eur Urol Focus 3:265–272

    Article  PubMed  Google Scholar 

  7. Hoshimoto S, Shingai T, Morton DL, Kuo C, Faries MB, Chong K, Elashoff D, Wang H-J, Elashoff RM, Hoon DS (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819–3826

    Article  PubMed  PubMed Central  Google Scholar 

  8. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1317

    Article  CAS  PubMed  Google Scholar 

  9. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Puleo CA, Coventry BJ (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599–609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206

    Article  PubMed  PubMed Central  Google Scholar 

  11. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459

    Article  PubMed  PubMed Central  Google Scholar 

  12. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, Mackenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, Mcmasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, Mckinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang H-J, Elashoff DA, Elashoff RM (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376:2211–2222

    Article  PubMed  PubMed Central  Google Scholar 

  13. Morton DL (2012) Overview and update of the phase III multicenter selective lymphadenectomy trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 29:699–706

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nicholl MB, Elashoff D, Takeuchi H, Morton DL, Hoon DS (2011) Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg 253:116

    Article  PubMed  Google Scholar 

  15. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, Mcmasters KM (2006) Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13:809–816

    Article  PubMed  Google Scholar 

  16. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte K-W, Lehmann P (2015) Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial. Am Soc Clin Oncol 17:757–767

    Google Scholar 

  17. Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, Sunderkötter C, Kaatz M, Schulte K-W, Lehmann P (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17:757–767

    Article  PubMed  Google Scholar 

  18. Melstrom LG, Taylor E, Kuk D, Frankel TL, Panageas K, Haydu L, Sabel MS, Thompson JF, Ariyan C, Coit DG (2014) International multi-institutional management and outcome of melanoma patients with positive sentinel lymph nodes in more than one nodal basin. Ann Surg Oncol 21:4324–4329

    Article  PubMed  Google Scholar 

  19. Balch CM, Morton DL, Gershenwald JE, Mcmasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF (2009) Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60:872–875

    Article  PubMed  Google Scholar 

  20. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA (2017) Melanoma staging: evidence-based changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472–492

    Article  PubMed  PubMed Central  Google Scholar 

  21. Murali R, Desilva C, McCarthy SW, Thompson JF, Scolyer RA (2012) Sentinel lymph nodes containing very small (< 0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Ann Surg Oncol 19:1089–1099

    Article  PubMed  Google Scholar 

  22. Scheri RP, Essner R, Turner RR, Ye X, Morton DL (2007) Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14:2861–2866

    Article  PubMed  Google Scholar 

  23. Ulmer A, Dietz K, Hodak I, Polzer B, Scheitler S, Yildiz M, Czyz Z, Lehnert P, Fehm T, Hafner C (2014) Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLoS Med 11:e1001604

    Article  PubMed  PubMed Central  Google Scholar 

  24. Werner-Klein M, Scheitler S, Hoffmann M, Hodak I, Dietz K, Lehnert P, Naimer V, Polzer B, Treitschke S, Werno C (2018) Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma. Nat Commun 9:595

    Article  PubMed  PubMed Central  Google Scholar 

  25. Carlson GW, Page AJ, Cohen C, Parker D, Yaar R, Li A, Hestley A, Delman KA, Murray DR (2008) Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg 248:378–386

    PubMed  Google Scholar 

  26. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C-H, Lee JJ, Balch CM, Ross MI (1998) Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16:2253–2260

    Article  CAS  PubMed  Google Scholar 

  27. Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang H-J, Elashoff R, Mozzillo N, Kelley MC, Thompson JF (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357

    Article  PubMed  Google Scholar 

  28. Koyanagi K, O‘Day SJ, Boasberg P, Atkins MB, Wang H-J, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J (2010) Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:2402–2408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Koyanagi K, O‘Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, Wang H-J, Elashoff RM, Takeuchi H, Umetani N (2005) Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 23:8057–8064

    Article  PubMed  Google Scholar 

  30. Lin S, Lam S, Ohe S, Tran K, Ramos I, Bhagat AA, Lim CT, O‘Day SJ, Foshag L, Hoon D (2017) Mo'nitoring of multimodality immune checkpoint inhibitor treatment efficacy in metastatic melanoma patients through molecular analysis of circulating tumor cells. AACR

    Google Scholar 

  31. Khoja L, Lorigan P, Zhou C, Lancashire M, Booth J, Cummings J, Califano R, Clack G, Hughes A, Dive C (2013) Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Investig Dermatol 133:1582–1590

    Article  CAS  PubMed  Google Scholar 

  32. Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M (2014) Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 14:423

    Article  PubMed  PubMed Central  Google Scholar 

  33. Lee J, Long G, Boyd S, Lo S, Menzies A, Tembe V, Guminski A, Jakrot V, Scolyer R, Mann G (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28:1130–1136

    Article  CAS  PubMed  Google Scholar 

  34. Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA (2015) Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6:42008

    PubMed  PubMed Central  Google Scholar 

  35. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R (2017) Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy. Clin Cancer Res 23:5729–5736

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Lee R, Gremel G, Marshall A, Myers KA, Fisher N, Dunn J, Dhomen N, Corrie P, Middleton MR, Lorigan P (2017) Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. Ann Oncol 29(2):490–496

    Article  PubMed Central  Google Scholar 

  37. Shinozaki M, O‘Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang H-J, Hoon DS (2007) Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 13:2068–2074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Koyanagi K, Mori T, O‘Day SJ, Martinez SR, Wang H-J, Hoon DS (2006) Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 66:6111–6117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mori T, O’Day S, Umetani N, Kuo C, Kitago M, Wilson L, Martinez S, Takeshima T-L, Milford R, Hoon D (2005) Circulating methylated DNA in serum predicts melanoma patients response to biochemotherapy. J Clin Oncol 23:7521–7521

    Article  Google Scholar 

  40. Mori T, Martinez SR, O‘Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang H-J (2006) Estrogen receptor-α methylation predicts melanoma progression. Cancer Res 66:6692–6698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lin SY, Huang SK, Huynh Kelly T, Salomon MP, Chang S-C, Marzese D, Lanman R, Talasaz A, Hoon DS (2018) Multiplex Gene Profiling of Cell-Free DNA in metastatic melanoma patients for monitoring disease. J Clin Oncol Precision Oncol. Manuscript Accepted

    Google Scholar 

  42. Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R (2008) Short German guidelines: malignant melanoma. JDDG: J Dtch Dermatol Ges 6:S9–S14

    Article  Google Scholar 

  43. Ono S, Oyama T, Lam S, Chong K, Foshag LJ, Hoon DS (2015) A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. Oncotarget 6:7053

    Article  PubMed  PubMed Central  Google Scholar 

  44. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M (2011) The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 61:187–193

    Article  CAS  PubMed  Google Scholar 

  45. Friedman EB, Shang S, de Miera EV-S, Fog JU, Teilum MW, Ma MW, Berman RS, Shapiro RL, Pavlick AC, Hernando E (2012) Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 10:155

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277

    Article  PubMed  Google Scholar 

  47. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F (2013) Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31:3083–3090

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746

    Article  CAS  PubMed  Google Scholar 

  49. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, Mcgale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846

    Article  PubMed  PubMed Central  Google Scholar 

  50. Mamounas EP, Kuehn T, Rutgers EJT, von Minckwitz G (2017) Current approach of the axilla in patients with early-stage breast cancer. Lancet

    Google Scholar 

  51. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, Julian TB, Mamounas EP, Wolmark N (2011) Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412–421

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, Morrow M, Leitch AM, Hunt KK, McCall LM, Abati A, Cote R (2011) Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 306:385–393

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, Giuliano AE (2009) Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol 27:4679–4684

    Article  PubMed  Google Scholar 

  54. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663

    Article  PubMed  Google Scholar 

  55. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14:297–305

    Article  PubMed  PubMed Central  Google Scholar 

  56. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA 318:918–926

    Article  PubMed  PubMed Central  Google Scholar 

  57. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802

    Article  CAS  PubMed  Google Scholar 

  59. Bidard FC, Proudhon C, Pierga JY (2016) Circulating tumor cells in breast cancer. Mol Oncol 10:418–430

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, de Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Caranana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414

    Article  PubMed  Google Scholar 

  61. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791

    Article  CAS  PubMed  Google Scholar 

  62. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695

    Article  PubMed  Google Scholar 

  63. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, Friedl TW, Lorenz R, Tesch H, Fasching PA, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Friese K, Pantel K, Janni W (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106

    Google Scholar 

  64. Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A (2016) Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res 22:2583–2593

    Article  CAS  PubMed  Google Scholar 

  65. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G (2007) Different prognostic value of cytokeratin-19 mrna–positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202

    Article  PubMed  Google Scholar 

  66. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D (2011) Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res 13:R60

    Article  PubMed  PubMed Central  Google Scholar 

  67. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27:2177–2184

    Article  CAS  PubMed  Google Scholar 

  68. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E (2007) Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 18:1623–1631

    Article  CAS  PubMed  Google Scholar 

  69. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24:3756–3762

    Article  CAS  PubMed  Google Scholar 

  70. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V (2015) Efficacy of lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer. PLoS One 10:e0123683

    Article  PubMed  PubMed Central  Google Scholar 

  71. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D (2012) Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 23:1744–1750

    Article  CAS  PubMed  Google Scholar 

  72. Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, Neubauer H (2013) Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 7:976–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. de Mattos-Arruda L, Caldas C (2016) Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. Mol Oncol 10:464–474

    Article  PubMed  Google Scholar 

  74. Page K, Hava N, Ward B, Brown J, Guttery D, Ruangpratheep C, Blighe K, Sharma A, Walker R, Coombes R (2011) Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer 104:1342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Dawson S-J, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B (2013) Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199–1209

    Article  CAS  PubMed  Google Scholar 

  76. Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R (2010) Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 87:83–91

    Article  CAS  PubMed  Google Scholar 

  77. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS (2006) Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 24:4270–4276

    Article  CAS  PubMed  Google Scholar 

  78. Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangpratheep C, Stebbing J, Payne R (2012) Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 22:220–231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, Vandenberg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH (2014) Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20:2643–2650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C (2010) Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat 120:461–467

    Article  CAS  PubMed  Google Scholar 

  81. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7:302ra133

    Article  PubMed  Google Scholar 

  82. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Ferno M, Ingvar C, Rose C, Bendahl PO, Ryden L, Borg A, Gruvberger-Saal SK, Jernstrom H, Saal LH (2015) Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 7:1034–1047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, Atochin I, Link DR, Griffiths AD, Pallier K (2013) Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59:1722–1731

    Article  CAS  PubMed  Google Scholar 

  84. Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hédelin G, Dalac S, Truchetet F, Michel C, Batard M-L (2008) Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France. Arch Dermatol 144:629–636

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge Dr. Ian Hutchinson, Editorial Services, for his support in editing of this manuscript, and Rebecca Gentry for her assistance in proofreading the manuscript.

Author information

Authors and Affiliations

  1. Department of Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA, USA

    Selena Y. Lin, Javier I. J. Orozco & Dave S. B. Hoon

Authors
  1. Selena Y. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier I. J. Orozco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dave S. B. Hoon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dave S. B. Hoon .

Editor information

Editors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Department of Otolaryngology, Department of Oncological Sciences, Tisch Cancer Institute, Black Family Stem Cell Institute, Mount Sinai School of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Julio A. Aguirre-Ghiso

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lin, S.Y., Orozco, J.I.J., Hoon, D.S.B. (2018). Detection of Minimal Residual Disease and Its Clinical Applications in Melanoma and Breast Cancer Patients. In: Aguirre-Ghiso, J. (eds) Biological Mechanisms of Minimal Residual Disease and Systemic Cancer. Advances in Experimental Medicine and Biology, vol 1100. Springer, Cham. https://doi.org/10.1007/978-3-319-97746-1_5

Download citation

Publish with us

Policies and ethics

Search

Navigation